Outcome of patients with adverse features
| . | No. . | % . | TRM . | Relapse . | DFS . | OS . |
|---|---|---|---|---|---|---|
| Age | ||||||
| Older than 30 y | 36 | 47 | 3% | 63% | 34% | 38% |
| 30 y or less | 41 | 53 | 12% | 23% | 64% | 66% |
| P | .18 | .0007 | .007 | .01 | ||
| Karyotype | ||||||
| t(4;11) or t(9;22) | 9 | 12 | 0% | 89% | 11% | 22% |
| Other | 68 | 88 | 9% | 35% | 55% | 57% |
| P | .99 | .0003 | .002 | .03 | ||
| Time to CR | ||||||
| More than 4 wk | 9 | 12 | 22% | 56% | 14% | 14% |
| 4 wk or less | 68 | 88 | 6% | 39% | 55% | 59% |
| P | .11 | .17 | .05 | .04 |
| . | No. . | % . | TRM . | Relapse . | DFS . | OS . |
|---|---|---|---|---|---|---|
| Age | ||||||
| Older than 30 y | 36 | 47 | 3% | 63% | 34% | 38% |
| 30 y or less | 41 | 53 | 12% | 23% | 64% | 66% |
| P | .18 | .0007 | .007 | .01 | ||
| Karyotype | ||||||
| t(4;11) or t(9;22) | 9 | 12 | 0% | 89% | 11% | 22% |
| Other | 68 | 88 | 9% | 35% | 55% | 57% |
| P | .99 | .0003 | .002 | .03 | ||
| Time to CR | ||||||
| More than 4 wk | 9 | 12 | 22% | 56% | 14% | 14% |
| 4 wk or less | 68 | 88 | 6% | 39% | 55% | 59% |
| P | .11 | .17 | .05 | .04 |
The relapse and TRM represent cumulative incidences at 10 years, and the DFS and OS figures, actuarial 10-year probabilities.